Identification and Preclinical Pharmacology of the -Secretase Modulator BMS-869780
Figure 9
Pharmacokinetics (PK) of BMS-869780 across species for prediction of human PK. Rats, dogs, and cynomolgus monkeys were dosed with BMS-869780 intravenously (IV ▲) at 1 mg/kg or oral nanosuspension (PO ●) at 5 mg/kg. Plasma concentrations of BMS-869780 were determined for up to 24 hours after the dose. (a) Rat. (b) Dog. (c) Cynomolgus monkey. The derived PK parameters are summarized in Table 4.